182 related articles for article (PubMed ID: 20638451)
21. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
23. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
[TBL] [Abstract][Full Text] [Related]
24. Vaccine shortages eliminate possibility for excess capacity in stockpiles.
Congeni BL
Pediatr Ann; 2004 Sep; 33(9):577-83. PubMed ID: 15462572
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of alternative polio immunization policies in South Africa.
Griffiths UK; Botham L; Schoub BD
Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
[TBL] [Abstract][Full Text] [Related]
26. Designing pediatric vaccine formularies and pricing pediatric combination vaccines using operations research models and algorithms.
Jacobson SH; Sewell EC; Allwine DA; Medina EA; Weniger BG
Expert Rev Vaccines; 2003 Feb; 2(1):15-9. PubMed ID: 12901593
[TBL] [Abstract][Full Text] [Related]
27. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
28. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
Thompson KM; Tebbens RJ
Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
[TBL] [Abstract][Full Text] [Related]
29. Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey.
Smith PJ; Nuorti JP; Singleton JA; Zhao Z; Wolter KM
Pediatrics; 2007 Nov; 120(5):e1165-73. PubMed ID: 17974712
[TBL] [Abstract][Full Text] [Related]
30. Establishing government-operated vaccine programs: an industry perspective.
Paradiso PR
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S118-20. PubMed ID: 16447132
[TBL] [Abstract][Full Text] [Related]
31. Optimal vaccine stockpile design for an eradicated disease: application to polio.
Tebbens RJ; Pallansch MA; Alexander JP; Thompson KM
Vaccine; 2010 Jun; 28(26):4312-27. PubMed ID: 20430122
[TBL] [Abstract][Full Text] [Related]
32. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
[TBL] [Abstract][Full Text] [Related]
33. Strengthening the supply of routinely administered vaccines in the United States: problems and proposed solutions.
Klein JO; Myers MG
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S97-103. PubMed ID: 16447139
[TBL] [Abstract][Full Text] [Related]
34. Update on vaccine liability in the United States: presentation at the National Vaccine Program Office Workshop on strengthening the supply of routinely recommended vaccines in the United States, 12 February 2002.
Evans G
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S130-7. PubMed ID: 16447135
[TBL] [Abstract][Full Text] [Related]
35. Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples.
Thompson KM; Duintjer Tebbens RJ
Risk Anal; 2016 Jul; 36(7):1487-509. PubMed ID: 25109229
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
Giorgi-Rossi P; Merito M; Borgia P
Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
38. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.
Santoli JM; Peter G; Arvin AM; Davis JP; Decker MD; Fast P; Guerra FA; Helms CM; Hinman AR; Katz R; Klein JO; Koslap-Petraco MB; Paradiso PR; Schaffner W; Whitley-Williams PN; Williamson DE; Gellin B;
JAMA; 2003 Dec; 290(23):3122-8. PubMed ID: 14679275
[TBL] [Abstract][Full Text] [Related]
39. Impact of the 2004-2005 influenza vaccine shortage on pediatric practice: a national survey.
McQuillan L; Daley MF; Stokley S; Crane LA; Beaty BL; Barrow J; Babbel C; Dickinson LM; Kempe A
Pediatrics; 2009 Feb; 123(2):e186-92. PubMed ID: 19171569
[TBL] [Abstract][Full Text] [Related]
40. Tiered use of inactivated influenza vaccine in the event of a vaccine shortage.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Aug; 54(30):749-50. PubMed ID: 16079741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
